Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Surgery may replace chemo for some testicular cancer patients

NCT ID NCT02537548

Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a surgery called retroperitoneal lymph node dissection (RPLND) can be used as the first treatment for men with early-stage testicular seminoma that has spread to lymph nodes in the abdomen. The goal is to see if this surgery can control the cancer while causing fewer long-term side effects than standard treatments like chemotherapy or radiation. About 55 men with small lymph nodes (1-3 cm) are being enrolled to track how many stay cancer-free after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Retroperitoneal lymph node dissection (RPLND) surgery
What this could lead to
If successful, this surgery could become a first-line treatment option for early-stage testicular seminoma, reducing the risk of long-term side effects like second cancers and heart disease.
What could go wrong
This is a small, early-phase trial with only 55 participants, so results may not apply to everyone. The surgery itself carries risks like bleeding, infection, and nerve damage, and some patients may still experience cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Aug 2015

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pure seminoma after orchiectomy presenting with isolated retropreritoneal lymphadenopathy OR stage I pure seminoma with isolated retroperitoneal relapse. Relapse should be within 3 years * Lymphadenopathy in the retroperitoneum: at least one lymph node 1-3 cm in greatest dimension, no lymph node \> 3 cm in greatest dimension, no more than 2 lymph nodes 1-3 cm in greatest dimension * Axial imaging of lymphadenopathy within 6 weeks of the date of RPLND * Retroperitoneal lymphadenopathy must be within the RPLND template * If there is borderline lymphadenopathy, defined as the largest retroperitoneal lymph node measuring 0.90 - 0.99 cm in the greatest dimension, an abdominal computed tomography (CT) scan should be repeated (recommend interval of 6 - 8 weeks); the same lymph node must demonstrate growth to \>= 1.0 cm in the greatest dimension * Biopsy is not required, though if biopsy of the retroperitoneal node(s) was obtained, pathology must be consistent with pure seminoma * Chest imaging (x-ray, CT or magnetic resonance imaging \[MRI\]) negative for metastasis no more than 6 weeks prior to the date of RPLND * Primary tumor excised by radical inguinal orchiectomy and pathology consistent with pure seminoma * Serum alpha fetoprotein (AFP) not more than 1.5 times upper limit of normal, beta-human chorionic gonadotropin (HCG), lactate dehydrogenase (LDH) (per the local laboratory assay) within 14 days of RPLND * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Ability to understand and the willingness to sign a written informed consent * Serum coagulation studies (INR/PTT) and platelet counts suitable for surgery per surgeon discretion. Exclusion Criteria: * Second primary malignancy * History of receiving chemotherapy or radiotherapy * Patients receiving any other investigational agent (s) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphadenopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphadenopathy lymphatic system disorder seminoma testicular seminoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphadenopathy Stage I testicular seminoma Stage II testicular seminoma

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Loma Linda University Medical Center

    Loma Linda, California, 92350, United States

  • Madigan Army Medical Center

    Tacoma, Washington, 98431, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903-2681, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21205, United States

  • Stanford University Hospitals & Clinics

    Stanford, California, 94305, United States

  • Stephenson Cancer Center, University of Oklahoma

    Oklahoma City, Oklahoma, 73104, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • UTSouthwestern Medical Center

    Dallas, Texas, 75390-9110, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University of Colorado Hospital - Aurora

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.